Text Size
Trial record 20 of 29 for:    Friedreich's Ataxia
Previous Study | Return to List | Next Study

Iron-Chelating Therapy and Friedreich Ataxia

This study has been completed.
Sponsor:
Information provided by:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00224640
First received: September 16, 2005
Last updated: March 3, 2009
Last verified: March 2007
History of Changes
  Purpose

Friedreich ataxia, an autosomal recessive condition, ascribed to frataxin gene expansion, has been shown to result from an iron- induced injury to the mitochondrial respiratory chain. Buffering free radicals with short-chain quinones (Idebenone) protects the patients against cardiomyopathy but not CNS involvement. Removing CNS iron should limit the impact of the neurological symptoms of the disease.


Condition Intervention Phase
Friedreich Ataxia
 Drug: Iron chelating intervention
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Iron-Chelating Therapy in Friedreich Ataxia. Study Phase I/II

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • assessment of iron overload at TO and month2 by imagery [ Time Frame: at months :0, 1 ,2 ,4 ,6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical (monthly) and biological parameter follow- up ( blood count, [ Time Frame: weekly ] [ Designated as safety issue: No ]
  • plasma iron, ferritin, transferrin and liver enzymes) [ Time Frame: every months ] [ Designated as safety issue: Yes ]

Enrollment: 15
Study Start Date: March 2005
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Iron chelating intervention
 Drug: Iron chelating intervention
Iron chelating intervention
Other Name: Iron chelating intervention

Detailed Description:

The current clinical trial is a monocentric open phase1-2 trial in the context of rare diseases framework, aimed to the goal of defining the tolerance/efficacy of the treatment.

Inclusion criteria: minimum age: 13 years Follow up in the Dept of Genetics, Hospital Necker-Enfants Malades, Paris, France

  Eligibility

Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Minimum age: 13 years
  2. Molecular confirmation of frataxin gene mutation
  3. Iron overload evaluation
  4. Presence of lactate
  5. Echography response to Idebenone treatment
  6. Urinary test of pregnancy for girls
  7. Sexual abstinence for men
  8. Information consent

Exclusion Criteria:

  1. No disturbance of iron metabolism
  2. No response to Idebenone
  3. Friedreich not confirmed
  4. Polynuclear neutrophils <2 x 109/L or hemoglobin < 8g/dL
  5. No participation to other trial
  6. Doubt regarding the compliance of the patient to protocol
  7. Impossibility to undergo X-ray examination or presence of iron material in the backbone
  8. Pregnant women
  9. Absence of social insurance.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00224640

Locations
France
Necker Hospital
Paris, France, 75015
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Arnold MUNNICH, Pr,MD,PhD Assistance Publique - Hôpitaux de Paris
  More Information

No publications provided

Responsible Party: Amel Ouslimany, Department Clinical Research of Developpement
ClinicalTrials.gov Identifier: NCT00224640     History of Changes
Other Study ID Numbers: P041201, PCR 05001
Study First Received: September 16, 2005
Last Updated: March 3, 2009
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Iron-chelating treatment

Additional relevant MeSH terms:
Ataxia
Friedreich Ataxia
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Spinocerebellar Degenerations
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
 Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases
Iron Chelating Agents
Iron
Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 18, 2013